FGTI-2734 manufacturers
- FGTI-2734
-
- $47.00 / 1mg
-
2025-11-10
- CAS:1247018-19-4
- Min. Order:
- Purity: 99.69%
- Supply Ability: 10g
- FGTI-2734
-
- $47.00 / 1mg
-
2025-11-10
- CAS:1247018-19-4
- Min. Order:
- Purity: 99.69%
- Supply Ability: 10g
|
| | FGTI-2734 Basic information |
| Product Name: | FGTI-2734 | | Synonyms: | FGTI-2734;2-Pyridinesulfonamide, N-[2-[(4-cyano-2-fluorophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]ethyl]-N-(cyclohexylmethyl)-;pancreatic,patient-derived,geranylgeranyl,farnesyl,inhibit,Farnesyl Transferase,mimetic,FGTI2734,Inhibitor,membrane,Ftase,FGTI-2734,KRAS,FGTI 2734,C-terminal,transferase,tumors,localization;FGTI-2734, 10 mM in DMSO;N-(2-((4-Cyano-2-fluorophenyl)((1-methyl-1H-imidazol-5-yl)methyl)amino)ethyl)-N-(cyclohexylmethyl)pyridine-2-sulfonamide | | CAS: | 1247018-19-4 | | MF: | C26H31FN6O2S | | MW: | 510.63 | | EINECS: | | | Product Categories: | | | Mol File: | 1247018-19-4.mol |  |
| | FGTI-2734 Chemical Properties |
| Boiling point | 770.1±70.0 °C(Predicted) | | density | 1.28±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO:50.0(Max Conc. mg/mL);97.92(Max Conc. mM) | | form | Solid | | pka | 6.60±0.10(Predicted) | | color | White to off-white |
| | FGTI-2734 Usage And Synthesis |
| Description | FGTI-2734 is a RAS C-terminal mimetic dual farnesyl transferase (FT) and geranylgeranyl transferase-1 (GGT-1) inhibitor. It can prevent membrane localization of KRAS, hence solving KRAS resistance problem and thwarting mutant KRAS patient-derived pancreatic tumors. | | Uses | FGTI-2734 is a RAS C-terminal mimetic dual farnesyl transferase (FT) and geranylgeranyl transferase-1 (GGT-1) inhibitor with IC50s of 250 nM and 520 nM for FT and GGT-1, respectively. FGTI-2734 can prevent membrane localization of KRAS, hence solving KRAS resistance problem and thwarting mutant KRAS patient-derived pancreatic tumors[1]. | | in vivo | FGTI-2734 (intraperitoneally; 100 mg/kg/daily for 18 to 25 days) only inhibits tumor growth in mutant KRAS-dependent tumors but not in mutant KRAS-independent tumors[1]. | Animal Model: | Male SCID-bg mice following injection of MiaPaCa2, L3.6pl, Calu6, A549, H460 and DLD1 cancer cells[1] | | Dosage: | 100 mg/kg | | Administration: | Intraperitoneally; daily; for 18 to 25 days | | Result: | Inhibited tumor growth in mutant KRAS-dependent tumors. |
| | target | FGTI-2734 is a RAS C-terminal mimetic dual farnesyl transferase (FT) and geranylgeranyl transferase-1 (GGT-1) inhibitor with IC50s of 250 nM and 520 nM for FT and GGT-1, respectively. | | References | [1] Kazi A, et al. Dual farnesyl and geranylgeranyl transferase inhibitor thwarts mutant KRAS-driven patient-derived pancreatic tumors. Clin Cancer Res. 2019 Jun 21. DOI:10.1158/1078-0432.CCR-18-3399 |
| | FGTI-2734 Preparation Products And Raw materials |
|